T 2552/16 (Ulipristal for treatment of fibroid-associated bleeding/USA & HRA PHARMA) of 23.11.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T255216.20201123
- Date of decision
- 23 November 2020
- Case number
- T 2552/16
- Online on
- 16 March 2021
- Petition for review of
- -
- Application number
- 09706347.3
- IPC class
- A61K 31/57A61P 5/36A61P 15/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- USE OF ULIPRISTAL FOR TREATING UTERINE FIBROIDS
- Applicant name
- The U.S.A. as represented by the Secretary,
Department of Health and Human Services
Laboratoire HRA Pharma - Opponent name
- Helm AG
Generics [UK] Ltd (trading as Mylan) - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56 (2007)European Patent Convention Art 123(2) (2007)European Patent Convention R 115(2) (2007)Rules of procedure of the Boards of Appeal Art 15(3) (2020)
- Keywords
- Inventive step - (no)
Amendments - allowable (no)
Oral proceedings - held in absence of party - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.